Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last €34.58 EUR
Change Today -1.97 / -5.40%
Volume 500.0
NK8 On Other Exchanges
As of 3:39 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

7475 Lusk Boulevard

San Diego, CA 92121

United States

Phone: 858-909-1800

Fax: 800-475-9134

NuVasive, Inc., a medical device company, focuses on developing minimally-disruptive surgical products and procedurally integrated solutions for the spine. The company’s product portfolio is focused on applications for spine fusion surgery, including biologics. The company’s principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide maximum visualization and are designed to enable safe and reproducible outcomes for the surgeon and the patient. The platform includes the company’s proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Many of the company’s products, including the individual components of its MAS platform can also be used in open or traditional spine surgery. The company’s spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are primarily used to enable surgeons access to the spine to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologic product line offerings used to aid the spinal fusion process or bone healing process include Osteocel Plus and Osteocel Pro allograft (donated human tissue) which are cellular matrix products containing viable mesenchymal stem cells (MSCs), as well as other allograft offerings, FormaGraft - a collagen synthetic product, and AttraX - a synthetic bone graft material that is available commercially only in select markets outside of the United States. The company also offers IOM services for insight into the nervous system during non-spine. The company’s MAS platform enables a lateral procedure known as eXtreme Lateral Interbody Fusion (XLIF), in which surgeons access the spine for a fusion procedure from the side of the patient’s body, rather than from the front or back. Its MaXcess instruments provide access to the spine in a manner that affords direct visualization and its nerve monitoring systems assist surgeons in the detection and navigation of critical nerves. The company also has product offerings that it continues to expand for procedures in the cervical spine. Its cervical product offering provides a set of solutions for cervical fusion surgery, including both allograft and CoRoent implants, as well as cervical plating and posterior fixation products. The NuVasive Solution — MAS with minimal tissue disruption The company’s MAS platform allows surgeons to perform a range of minimally-disruptive spine procedures in all regions of the spine and from various surgical approaches, while overcoming the shortcomings of traditional minimally invasive spine surgical techniques. The platform is designed to treat a range of spinal pathologies while accommodating a surgeon’s preferred surgical technique. The company’s MAS platform combines three product categories: its MaXcess retractors, its specialized implants, and its nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves while directing customized access to the spine for implant delivery. MaXcess also allows surgeons to use traditional instruments in a minimally-disruptive and less traumatic manner while the company’s biologics offerings complement its MAS\platform by facilitating bone growth and fusion. The company also offers various specialized implants that enable the maximization of disc height restoration and structural support while conforming to the anatomical requirements of the patient. The company’s products facilitate minimally-disruptive applications of various spine surgery procedures, including lumbar and thoracic fusion procedures in which the surgeon approaches the spine through the patient’s back, side or abdomen; cervical fusion procedures for either the posterior occipito-cervico-thoracic region or the anterior cervical region; and decompression, which is


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €34.58 EUR -1.97

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Globus Medical Inc $22.61 USD +0.21
Integra LifeSciences Holdings Corp $55.49 USD -0.04
LivaNova PLC $55.44 USD +1.44
Masimo Corp $35.41 USD +0.24
Wright Medical Group NV $15.64 USD +0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation NK8 Industry Range
Price/Earnings 33.1x
Price/Sales 2.5x
Price/Book 3.0x
Price/Cash Flow 26.1x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NUVASIVE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at